1. Articles from ncbi.nlm.nih.gov

  2. 25-48 of 1715 « 1 2 3 4 5 ... 70 71 72 »
    1. Pediatric Cancer Immunotherapy: Opportunities and Challenges.

      Pediatric Cancer Immunotherapy: Opportunities and Challenges.

      Paediatr Drugs. 2018 Jun 12;:

      Authors: Wedekind MF, Denton NL, Chen CY, Cripe TP

      Abstract Cancer immunotherapies, widely heralded as transformational for many adult cancer patients, are becoming viable options for selected subsets of pediatric cancer patients.

      Read Full Article
      Mentions: Immunotherapy
    2. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.

      The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.

      Arch Toxicol. 2018 Jun 09;:

      Authors: Kolbinger FR, Koeneke E, Ridinger J, Heimburg T, Müller M, Bayer T, Sippl W, Jung M, Gunkel N, Miller AK, Westermann F, Witt O, Oehme I

      Read Full Article
    3. Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy.

      Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy.

      Bull Math Biol. 2018 Jun 14;:

      Authors: He Y, Kodali A, Wallace DI

      Abstract Neuroblastoma is the leading cause of cancer death in young children. Although treatment for neuroblastoma has improved, the 5-year survival rate of patients still remains less than half.

      Read Full Article
      Mentions: Treatment
    4. ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma.

      ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma.

      Proc Natl Acad Sci U S A. 2018 Jun 25;:

      Authors: Pieraccioli M, Nicolai S, Pitolli C, Agostini M, Antonov A, Malewicz M, Knight RA, Raschellà G, Melino G

      Abstract Derangement of cellular differentiation because of mutation or inappropriate expression of specific genes is a common feature in tumors.

      Read Full Article
      Mentions: MYCN
    5. Radioiodine (131I) therapies performed in a paediatric hospital: facilities and procedures.

      Radioiodine (131I) therapies performed in a paediatric hospital: facilities and procedures.

      Australas Phys Eng Sci Med. 2018 Jun 25;:

      Authors: Bibbo G, Benger T, Sigalas V, Kirkwood I

      Abstract Radioiodine (131I) therapies on younger children with thyroid cancer and neuroblastoma can be challenging as they are required to be isolated for a period of time due to radiation safety concerns. At our hospital these therapies are performed in a purpose-built child-friendly therapy room.

      Read Full Article
    6. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma.

      Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma.

      J Clin Invest. 2018 Jun 25;:

      Authors: Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, Bayır H, Abhari BA, Angeli JPF, Choi SM, Meul E, Heyninck K, Declerck K, Chirumamilla CS, Lahtela-Kakkonen M, Van Camp G, Krysko DV, Ekert PG, Fulda S, De Geest BG, Conrad M, Kagan VE, Berghe WV, Vandenabeele P, Berghe TV

      Read Full Article
    7. Favorable prognostic role of tropomodulins in neuroblastoma.

      Favorable prognostic role of tropomodulins in neuroblastoma.

      Oncotarget. 2018 Jun 05;9(43):27092-27103

      Authors: Bettinsoli P, Ferrari-Toninelli G, Bonini SA, Guarienti M, Cangelosi D, Varesio L, Memo M

      Abstract Neuroblastoma is a pediatric tumor of the sympatoadrenal lineage of the neural crest characterized by high molecular and clinical heterogeneity, which are the main causes of the poor response to standard multimodal therapy.

      Read Full Article
    8. ERα36 gene silencing promotes tau protein phosphorylation, inhibits cell proliferation, and induces apoptosis in human neuroblastoma SH-SY5Y cells.

      ERα36 gene silencing promotes tau protein phosphorylation, inhibits cell proliferation, and induces apoptosis in human neuroblastoma SH-SY5Y cells.

      FASEB J. 2018 Jun 22;:fj201701386

      Authors: Wang HB, Li T, Ma DZ, Zhi H

      Abstract Neuroblastoma is the most common cancer in infants and the third most common cancer in children after leukemia and brain cancer.

      Read Full Article
    9. LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis.

      LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis.

      Clin Cancer Res. 2018 Jun 20;:

      Authors: Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, De Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C

      Read Full Article
      Mentions: MYCN LDH
    10. Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Int J Cancer. 2018 Jun 21;:

      Authors: Norsker FN, Rechnitzer C, Cederkvist L, Tryggvadottir L, Madanat-Harjuoja LM, Øra I, Thorarinsdottir HK, Vettenranta K, Bautz A, Schrøder H, Hasle H, Winther JF

      Read Full Article
    11. Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?"

      Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?"

      Pediatr Blood Cancer. 2018 Jun 19;:e27248

      Authors: Flynn N, LeFebvre A, Messahel B, Hogg SL

      Abstract Measurement of the urine catecholamine metabolites homovanillic acid (HVA) and vanillylmandelic acid (VMA) are the standard method for detecting disease recurrence in neuroblastoma.

      Read Full Article
    12. Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma.

      Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma.

      Pediatr Transplant. 2018 Jun 19;:e13240

      Authors: Liu APY, Lee PPW, Kwok JSY, Leung RYY, Chiang AKS, Ha SY, Cheuk DKL, Chan GCF

      Abstract Relapsed/refractory NB carries a bleak outcome, warranting novel treatment options. HaploHSCT induces a graft-versus-NB effect via natural killer cell alloreactivity.

      Read Full Article
    13. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Clin Nucl Med. 2018 Jun 19;:

      Authors: Willegaignon J, Crema KP, Oliveira NC, Pelissoni RA, Coura-Filho GB, Sapienza MT, Buchpiguel CA

      Read Full Article
    14. Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      J Adv Pract Oncol. 2017 Jan-Feb;8(1):44-55

      Authors: Armideo E, Callahan C, Madonia L

      Abstract Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials.

      Read Full Article
    15. Lymph microvascularization as a prognostic indicator in neuroblastoma.

      Lymph microvascularization as a prognostic indicator in neuroblastoma.

      Oncotarget. 2018 May 25;9(40):26157-26170

      Authors: Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Gironella M, Ritort F, Cañete A, Bueno G, Navarro S, Noguera R

      Abstract Neuroblastoma is the most common extra-cranial solid pediatric cancer and causes approximately 15% of all childhood deaths from cancer.

      Read Full Article
    16. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      J Natl Compr Canc Netw. 2018 Jun;16(6):683-691

      Authors: Eterovic AK, Maher OM, Chandra J, Chen K, Huse J, Zaky W

      Abstract Metachronous neoplasms have rarely been reported in patients with neuroblastoma.

      Read Full Article
      Mentions: ALK
    17. Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Cancer. 2018 Jun 11;:

      Authors: Zheng DJ, Krull KR, Chen Y, Diller L, Yasui Y, Leisenring W, Brouwers P, Howell R, Lai JS, Balsamo L, Oeffinger KC, Robison LL, Armstrong GT, Kadan-Lottick NS

      Read Full Article
    18. President Signs STAR Act for Kids' Cancers.

      President Signs STAR Act for Kids' Cancers.

      Cancer Discov. 2018 Jun 07;:

      Authors:

      Abstract On June 5, President Donald Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research Act, which aims to support pediatric cancer research by expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.

      PMID: 29880581 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Treatment
    19. Predicting clinical outcome of neuroblastoma patients using an integrative network-based approach.

      Predicting clinical outcome of neuroblastoma patients using an integrative network-based approach.

      Biol Direct. 2018 Jun 07;13(1):12

      Authors: Tranchevent LC, Nazarov PV, Kaoma T, Schmartz GP, Muller A, Kim SY, Rajapakse JC, Azuaje F

      Abstract BACKGROUND: One of the main current challenges in computational biology is to make sense of the huge amounts of multidimensional experimental data that are being produced.

      Read Full Article
    20. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

      Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

      Oncogene. 2018 Jun 07;:

      Authors: Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly EP, Kandel JJ, Rajbhandari P, Silva JM, Califano A, Yamashiro DJ

      Read Full Article
      Mentions: MYCN
    25-48 of 1715 « 1 2 3 4 5 ... 70 71 72 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video